Navigation Links
DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research
Date:9/12/2013

FREMONT, Calif., Sept. 12, 2013 /PRNewswire/ -- DiscoveRx Corporation, through its BioSeek division, today announced the release of an industry-first, primary human cell-based assay platform for oncology research. Consisting of primary human cell-based tumor-host model systems, this new BioMAP panel enables researchers to easily assess the phenotypic impact of candidate compounds on tumor microenvironment biology to better predict in vivo drug activities and forecast potential clinical outcomes with respect to drug efficacy and safety.

(Logo: http://photos.prnewswire.com/prnh/20130912/SF78575LOGO)

"These oncology-focused BioMAP® systems will support predictive and physiologically relevant cancer compound development from early discovery through pre-clinical development stages," said Ellen Berg, Ph.D., Scientific Director and General Manager of BioSeek. "They capture human tumor-host activities that can be modulated by a number of clinically relevant mono-therapies as well as drug combinations involving small molecule chemotherapeutics and biologics. Such BioMAP® models recapitulate complex interactions between tumor cells, stromal and/or vascular tissue and recruited, infiltrating immune cells to the tumor."

Despite a fair number of cancer drugs gaining approval for clinical use, late-stage compound attrition still remains a major issue in anticancer drug development. A critical need remains for pre-clinical models that can serve as better predictors of success in clinical trials. Scientific evidence is mounting that combination therapies using previously approved oncology drugs can be more efficacious, safe and successful than traditional mono-therapies, making the need for predictive in-vivo models more apparent. By virtue of the fact that the two compounds selected for combination therapy would have been developed independently, determining the appropriate therapeutic dosing for such combinations also continues to be technically challenging. The ability to test drug combinations in predictive models such as BioMAP can support the testing of pre-clinical strategies involving both development compounds and approved drugs.

For pricing inquiries, request for collaboration and project proposals, please send an email to busdev@bioseekinc.com.

About BioMAP

BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative activity profiles of each potential drug, assisting in the selection and development of new drug candidates. For more information on BioMAP drug discovery services, visit http://www.biomapsystems.com.

About DiscoveRx

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, CA, San Francisco, CA and Birmingham, England. DiscoveRx is a leading provider of next generation proprietary platforms for both target-based and phenotypic based drug discovery. The company holds extensive intellectual property for its core technology platforms 1) PathHunter®, HitHunter®and  InCELL Hunter™ : β-galactosidase based enzyme fragment complementation, 2) KINOMEscan® : in vitro binding assay platform and 3) BioMAP®: A three part drug discovery solution consisting of BioMAP system, proprietary database, and predictive analytics tools. Utilizing these proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of over 1000 target based and primary cell based assay solutions for Oncology, Metabolic Disease, Inflammation, CNS and Cardiovascular drug discovery research. Many of DiscoveRx's innovative solutions have been widely adopted in pharmaceutical, biotechnology and academic laboratories worldwide. For more information, visit www.discoverx.com


'/>"/>
SOURCE DiscoveRx Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Entomological Society of America announces 2013 awardees
2. Entomological Foundation announces 2013 Insect Science Award winners
3. Chair Mats of Glass Company Clearly Innovative Announces the Launch of 20 New Dealers in the Midwest
4. Diamond Vision Announces New and Generous Promotion on its iLASIK in NYC Procedure
5. Physiotherapy in Singapore Clinic Urbanrehab Pte Ltd Announces the Opening of an Additional Location
6. Elsevier announces the launch of a new open access journal: Water Resources and Industry
7. NOAA announces additions to National System of Marine Protected Areas
8. FASEB announces BioArt image and video competition winners
9. Entomological Society of America announces 2013 fellows
10. Neurotechnology Announces NCheck Bio Attendance 2.0 Biometric Time and Attendance Software
11. Bert L. & N. Kuggie Vallee Foundation announces first recipients of its Young Investigator Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), a ... medical radioisotope applications for the treatment of prostate, brain, ... its financial results for the second quarter and six ... --> --> ... fiscal 2016, which ended December 31, 2015, a 12% ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... three states, announced today the promotion of two long-standing principal investigators (PI) to ... Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research ...
Breaking Biology Technology: